These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 18199797)

  • 1. Sirolimus reduces polycystic liver volume in ADPKD patients.
    Qian Q; Du H; King BF; Kumar S; Dean PG; Cosio FG; Torres VE
    J Am Soc Nephrol; 2008 Mar; 19(3):631-8. PubMed ID: 18199797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study.
    Davis S; Gralla J; Chan L; Wiseman A; Edelstein CL
    Transplant Proc; 2018 Jun; 50(5):1243-1248. PubMed ID: 29880342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
    Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
    N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus therapy to halt the progression of ADPKD.
    Perico N; Antiga L; Caroli A; Ruggenenti P; Fasolini G; Cafaro M; Ondei P; Rubis N; Diadei O; Gherardi G; Prandini S; Panozo A; Bravo RF; Carminati S; De Leon FR; Gaspari F; Cortinovis M; Motterlini N; Ene-Iordache B; Remuzzi A; Remuzzi G
    J Am Soc Nephrol; 2010 Jun; 21(6):1031-40. PubMed ID: 20466742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
    Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
    J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option].
    Serra AL; Wüthrich RP
    Praxis (Bern 1994); 2009 Dec; 98(25):1511-6. PubMed ID: 20013687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP; Kistler AD; Serra AL
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized intervention studies in human polycystic kidney and liver disease.
    Schrier RW
    J Am Soc Nephrol; 2010 Jun; 21(6):891-3. PubMed ID: 20431043
    [No Abstract]   [Full Text] [Related]  

  • 11. Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    Liu YM; Shao YQ; He Q
    Transplant Proc; 2014; 46(1):66-74. PubMed ID: 24507028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
    van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
    Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.
    Riegersperger M; Herkner H; Sunder-Plassmann G
    Trials; 2015 Apr; 16():182. PubMed ID: 25899445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.
    Soliman A; Zamil S; Lotfy A; Ismail E
    Transplant Proc; 2012 Dec; 44(10):2936-9. PubMed ID: 23195001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
    Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
    Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?
    Canaud G; Knebelmann B; Harris PC; Vrtovsnik F; Correas JM; Pallet N; Heyer CM; Letavernier E; Bienaimé F; Thervet E; Martinez F; Terzi F; Legendre C
    Am J Transplant; 2010 Jul; 10(7):1701-6. PubMed ID: 20642692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin analogues for treatment of polycystic liver disease.
    Gevers TJ; Drenth JP
    Curr Opin Gastroenterol; 2011 May; 27(3):294-300. PubMed ID: 21191289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
    N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
    Renken C; Fischer DC; Kundt G; Gretz N; Haffner D
    Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.